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Background: Attention-deficit/hyperactivity disorder (ADHD) symptom presentation across 
age and sex has not been fully elucidated. The present post hoc analyses qualitatively explored 
the baseline levels of ADHD symptomatology across subgroups in two clinical trials of children 
and adults with ADHD to elucidate differences in participant presentation. The response to 
treatment was examined to determine patterns of response among items of the ADHD Rating 
Scale IV.
Methods: Exploratory post hoc analyses of ADHD Rating Scale IV item scores were 
 conducted on data from two 4-week placebo-controlled trials in children (6–12 years) and in 
adults (18–55 years) with ADHD. Baseline and endpoint mean item scores were determined 
for subgroups defined by age (6–9, 10–12, 18–39, and 40–55 years) and sex.
Results: The baseline mean item scores were generally numerically similar for all age-by-sex 
subgroups. The inattention (IA) items were numerically higher than hyperactivity/impulsivity 
(H/I) items among older children and adults. The endpoint mean item scores were numerically 
lower after lisdexamfetamine dimesylate treatment for IA and H/I items in all subgroups.
Conclusion: These results suggest that regardless of age or sex, baseline IA and H/I 
 symptom profiles were comparable; however, IA vs H/I symptoms were more severe in older 
 participants. In all age-by-sex subgroups, IA and H/I symptoms appeared to decrease after 
active treatment.
Keyword: ADHD symptom items
Introduction
Attention-deficit/hyperactivity disorder (ADHD), characterized by hyperactiv-
ity,  impulsivity, and attention abnormalities, affects approximately 8% of children 
(aged 8 to 15 years) in the United States.1 Recent data from the US Centers for Disease 
Control and Prevention2 reported 5.4 million children with ADHD by 2007, a 22% 
increase over statistics from 2003. While most frequently identified in childhood, 
ADHD persists into adulthood in ∼50%3 to 75% of cases,4 impacting an estimated 
4.4% of US adults (aged 18 to 44 years).5 Relatively little is known about whether 
and how specific ADHD symptoms and their response to treatment may be related to 
demographic variables, such as patient age or sex. A clear understanding of the rela-
tionship between patient variables, such as age and sex, and expression of  symptoms 





might help clinicians better understand the needs of indi-
vidual patients and better approach the management of 
ADHD symptoms.
The relationship of patient variables, such as age and sex, 
to the developmental course of ADHD symptom presenta-
tion has been the focus of research interest in recent years. 
In longitudinal studies, as participants mature, symptoms of 
inattention (IA) appear to persist, while symptoms of hyper-
activity or impulsivity (H/I) are more likely to diminish.6−8 
In line with such findings, other studies have found rates of 
H/I symptoms to be age related9,10; in one investigation of 
adult ADHD, Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition−Text Revision (DSM-IV-TR)–
defined symptoms reported by more than 90% of subjects 
were consistent with IA, or a combined subtype, while only 
2% reported predominantly H/I-type symptoms.10,11 Results 
of a recent survey of data from the National Comorbidity 
Survey Replication and a large managed health care plan 
found a greater persistence of childhood IA vs H/I symptoms 
in adults with ADHD.12 However, these apparent age-related 
differences in symptom presentation may reflect an issue with 
diagnostic criteria rather than an actual change. Hyperactivity 
may be manifested, in adults, with feelings of restlessness or 
difficulty waiting.13,14 Adults with ADHD also often report or 
exhibit impulsivity,15−17 marked clinically by such behaviors 
as explosive emotional episodes,14 quitting jobs, impulsive 
aggression, binge drinking, dangerous vehicle driving, sub-
stance use, and dropping out of school.18 To allow for the full 
assessment and breadth of the adult presentation of ADHD 
symptoms, a set of adult prompts or descriptions of example 
adult behaviors has been developed. These prompts enhance 
the ability of patients and raters to identify adult symptoms 
and can be inserted into symptom rating scales, such as the 
ADHD Rating Scale IV (ADHD-RS-IV).9
ADHD symptom presentation also varies by sex; thus, 
school-aged girls with ADHD are diagnosed more often with 
the predominantly IA subtype than are boys with ADHD.19−21 
In one investigation, the IA subtype accounted for 34% of 
ADHD cases in girls vs 22% of cases in boys.21 In adults, it 
is unclear whether this subtype pattern holds true. Although 
women and men appear equally likely to be diagnosed with 
ADHD and the majority receive a diagnosis of combined 
type, it is unclear whether subtype expression differs by sex 
and whether the higher proportion of IA subtype seen in 
female children holds for adult women.22,23 Again, the degree 
to which such findings reflect limitations of the current DSM-
IV-TR diagnostic criteria, sampling bias, or true symptom 
differences/similarities among women and men with ADHD 
is not known. Another limitation may be the agreement or 
concordance of rating between patient self-assessment of 
symptoms and informant assessment for both current adult 
symptoms and prior childhood symptoms. A study by Zucker 
et al24 found a moderate correlation between self- and infor-
mant ratings, with sex as a moderating factor.
Psychostimulants, including formulations containing 
amphetamines or methylphenidate, are a mainstay in the 
pharmacological treatment of ADHD for children and 
adults.25,26 Response to stimulant therapy is robust in both 
children27 and adults.28 Lisdexamfetamine dimesylate (LDX) 
is a long-acting prodrug stimulant indicated for the treatment 
of ADHD in children (aged 6 to 12 years), adolescents (aged 
13 to 17 years), and adults.29 LDX is currently approved for 
treatment of ADHD in the United States, Canada, and Brazil. 
In a 4-week, randomized controlled trial in children30 and 
similarly, in a 4-week, randomized controlled trial in adults, 
with ADHD,31 LDX was shown to be effective vs placebo in 
reducing ADHD symptoms, as assessed by a global improve-
ment measure.
Analysis of individual DSM-IV-TR–defined symptoms, 
based on symptom scores of the corresponding ADHD-RS-
IV item questions, can provide useful information about 
symptom presentation similarities and differences across 
patient subgroups of different ages and sexes. The purpose 
of the current post hoc subgroup analysis was to describe the 
profile of individual DSM-IV-TR symptoms of ADHD, as 
assessed by ADHD-RS-IV scores on individual items, both at 
baseline and in the change from baseline with LDX treatment, 
in the children and adults with ADHD who participated in 
two double-blind, placebo-controlled, parallel-group, 4-week 
studies of the efficacy of LDX vs placebo. A number of other 
clinical trials of LDX in children or adults were not included, 
based on dissimilar study design features, such as open-label, 
unblinded design, crossover design, or length of study.32−37 The 
present analyses explored the levels of ADHD symptomatol-
ogy across the subgroups in these two studies, at baseline 
and after treatment, to elucidate qualitative differences in 
participant presentation. The response to treatment was also 
examined to determine patterns of response among items.
Methods
study overview
An exploratory set of post hoc analyses was based on data 
from two similarly designed 4-week, multicenter, placebo-
controlled, double-blind, parallel-group, forced dose-
escalation trials in both children (aged 6 to 12 years)30 and 
adults (aged 18 to 55 years)31 with ADHD. Participants were 




Effects of age/sex in LDX trials
randomly assigned in either a 1:1:1:1 ratio (pediatric study) 
or a 2:2:2:1 ratio (adult study) to receive once-daily, oral 
LDX (30, 50, or 70 mg) or placebo for 4 weeks. Each study 
included a screening/washout phase and a 4-week, double-
blind treatment phase with LDX vs placebo. After screening, 
all eligible participants were randomized to receive LDX or 
placebo. The LDX treatment was initiated with the 30-mg/d 
dose for all participants randomized to receive LDX. For par-
ticipants assigned the higher LDX doses of 50 or 70 mg/d, the 
dose was increased in 20-mg increments at weekly intervals 
until the assigned dose was achieved.
The investigations were performed in accordance with the 
Declaration of Helsinki and the International Conference on 
Harmonization guidelines for Good Clinical Practice. Before 
initiation of any study procedures, the parents/guardians of 
all prospective pediatric participants and all adult partici-
pants provided informed consent, and pediatric participants 
gave their assent after receiving written information and an 
explanation of what the study involved.30,31
Participants
The study enrollment requirements have been described in 
detail previously.30,31 Briefly, otherwise healthy children (aged 
6 to 12 years) diagnosed with ADHD (H/I or combined sub-
type) or adults (aged 18 to 55 years) diagnosed with ADHD 
(irrespective of subtype) according to DSM-IV-TR criteria, 
based on psychiatric interview, were enrolled. A baseline 
ADHD-RS-IV score $28 was required. Excluded were 
individuals with ADHD IA subtype; comorbid psychiatric 
disorder; history of seizures (excluding febrile seizures); 
tic disorder; current diagnosis or family history of Tourette 
disorder; specific cardiac conditions, hypertension, taking 
medications affecting blood pressure or heart rate (with the 
exception of ADHD therapy), or a family history of cardiac 
conditions reflecting increased potential risk for sudden death; 
significantly overweight or obese participants; those for whom 
stimulant therapy was contraindicated; pregnant or nursing 
females; those with a positive urine drug result at screening 
or baseline; and those whose current medication use might 
confound the results of the study or increase risk to the par-
ticipant. Oppositional defiant disorder and conduct disorder 
were not exclusion criteria for participation in these studies.
Treatment outcomes
The primary outcome in both trials was change in the 
clinician-rated ADHD-RS-IV total score from baseline to 
endpoint; for the adult trial, the ADHD-RS-IV with adult 
prompts9 was used. Treatment endpoint was defined as the 
last postrandomization treatment week for which a valid 
ADHD-RS-IV score was obtained. The ADHD-RS-IV, 
administered at baseline and each postrandomization visit, 
contains 18 items (as listed in Figures 1−3) corresponding 
to DSM-IV-TR ADHD diagnostic criteria.38 The items are 
scored between 0 (no symptoms) and 3 (severe symptoms). 
In addition to the ADHD-RS-IV total score (range 0 to 54), 
the instrument can be subdivided into two subscales: IA 
(odd-numbered items) and H/I (even-numbered items), each 
with possible scores ranging from 0 to 27.
safety assessments
The safety assessments included spontaneously reported 
adverse events (AEs), vital signs, electrocardiogram (ECG), 
routine clinical laboratory assessments, and physical exami-
nation (eg, height and weight). Safety findings for these trials 
have been previously described in detail30,31 and will not be 
further discussed in the current report. Treatment-emergent 
AEs (TEAEs) referred to events with onset after the first date 
of treatment and no later than 3 days following the termina-
tion of treatment.
statistical analyses
These exploratory post hoc analyses examined individual 
scores for each of the 18 ADHD-RS-IV items among sub-
groups of participants, defined according to age and sex, 
in the treated population (ie, randomized participants who 
received double-blind treatment with at least one postran-
domization primary measure). For this analysis, participants 
were dichotomized into male and female subgroups and were 
further divided according to age: 6 to 9 years, 10 to 12 years, 
18 to 39 years, and 40 to 55 years. The subgroups of those 
aged 6 to 9 years and 10 to 12 years were chosen to differen-
tiate childhood from the period of transition to adolescence; 
similarly, the adult subgroups, aged 18 to 39 years and 40 to 
55 years, were chosen to differentiate young adulthood from 
middle age. Individual ADHD-RS-IV item scores with stan-
dard deviations (SD) at baseline and endpoint were assessed by 
these age-by-sex subgroups. For the purposes of these analyses, 
the results were collapsed across the LDX dose groups. These 
were exploratory post hoc analyses with small sample sizes 
in certain subgroups; therefore, further comparative statistical 
analyses were not performed.
Results
Participants
Participant disposition and demographic characteristics 
(Table 1) have been presented in detail in prior reports.30,31 





Briefly, in the pediatric and adult trials, respectively, 290 and 
420 participants enrolled and were randomized. Of these, the 
treated populations comprised 285 and 414 participants, respec-
tively. Among participants who discontinued the pediatric or 
adult trials, TEAEs were the most frequent reason given for 
discontinuation (LDX = 20, placebo = 1 in the pediatric trial; 
LDX = 20, placebo = 1 in the adult trial). Among the participants 
in both trials, more than half were male. In the pediatric trial, 
approximately half were Caucasian; in the adult trial, a large 
majority were Caucasian. Among the 421 males in the treated 
populations of both studies, 119 were aged 6 to 9 years, 78 were 
aged 10 to 12 years, 153 were aged 18 to 39 years, and 71 were 
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1. Fails to give close attention to details or makes
    careless mistakes in schoolwork
3. Has difficulty sustaining attention in tasks or
    play activities
4. Leaves seat in classroom or in other situations
    in which remaining seated is expected
5. Does not seem to listen when spoken to directly
6. Runs about or climbs excessively in situations
    in which it is inappropriate
7. Does not follow through on instructions and fails
    to finish work
8. Has difficulty playing or engaging in leisure
    activities
9. Has difficulty organizing tasks and activities
10. Is “on the go” or acts as if “driven by a motor”
11. Avoids tasks that require sustained mental effort
12. Talks excessively
13. Loses things necessary for tasks or activities
14. Blurts out answers before questions have
      been completed
15. Is easily distracted
16. Has difficulty awaiting turn
17. Is forgetful in daily activities
18. Interrupts or intrudes on others
Placebo all subjects: (n = 72)
LDX all subjects: (n = 213)
2. Fidgets with hands or feet or squirms in seat
4321
ADHD-RS-IV item score, mean ± SD
0−1 4321
ADHD-RS-IV item score, mean ± SD
0−1
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Figure 1 aDhD-rs-iV mean item scores overall at baseline and endpoint, in (A) the child study and (B) the adult study.
Notes: © 1998 Guildford Press. Adapted with permission from DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical 
Interpretation. New York, NY: Guilford Press; 1998.38 Odd numbers = inattention items; even numbers = hyperactivity/impulsivity items. Adult prompts were used in the adult 
study. Bold text represents a hyperactivity/impulsivity item.
Abbreviations: ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale IV; LDX, lisdexamfetamine dimesylate; SD, standard deviation.
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Placebo boys aged 10–12 years: (n = 25)
Placebo girls aged 10–12 years: (n = 12)
LDX boys aged 10–12 years: (n = 53)
LDX girls aged 10–12 years: (n = 23)
Placebo boys aged 6–9 years: (n = 25)
Placebo girls aged 6–9 years: (n = 10)
LDX boys aged 6–9 years: (n = 94)
LDX girls aged 6–9 years: (n = 43)
A
B
Figure 2 ADHD-RS-IV mean item scores by pediatric age and sex subgroups at baseline and endpoint. (A) Shows boys and girls aged 6 to 9 years; (B) shows boys and girls 
aged 10 to 12 years.
Notes: © 1998 Guildford Press. Adapted with permission from DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical 
Interpretation. New York, NY: Guilford Press; 1998.38 Odd numbers = inattention items; even numbers = hyperactivity/impulsivity items. Adult prompts were used in the adult 
study. Bold text represents a hyperactivity/impulsivity item.
Abbreviations: ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale IV; LDX, lisdexamfetamine dimesylate; SD, standard deviation.
aged 40 to 55 years. Among the 278 females in the treated 
populations, 53 were aged 6 to 9 years, 35 were aged 10 to 
12 years, 109 were aged 18 to 39 years, and 81 were aged 40 
to 55 years. Almost all (except one participant) in both trials 
suffered from moderate to severe/extreme ADHD symptoms at 
baseline, as rated by the Clinical Global Impressions-Severity 
scale.
Overall aDhD-rs-iV mean item scores at baseline 
and after treatment
As described in the previous reports of the primary study 
analyses, all doses of LDX showed significant improvement 
vs placebo in mean changes from baseline to endpoint in 
the ADHD-RS-IV total mean item scores (P , 0.0001).30,31 
For the current post hoc analyses, numerical differences 





from baseline to endpoint in the actively treated population 
vs placebo were observed for all 18 of the ADHD-RS-IV 
mean item scores (Figure 1) in both children and adults. In 
the adult data, there was an observable pattern of numerically 
lower mean item baseline scores for the H/I symptoms (even-
numbered items) than for the IA symptoms (odd-numbered 
items) that was not seen in the child data. All items, however, 
showed numerical decreases at endpoint in both children 
and adults.
analysis of individual aDhD-rs-iV mean item scores 
by age and sex
For the subgroups of boys and girls aged 6 to 9 years, the 
mean item baseline scores were numerically similar for 
ItemsBaseline Endpoint
1. Fails to give close attention to details or makes
    careless mistakes in schoolwork
3. Has difficulty sustaining attention in tasks or
    play activities
4. Leaves seat in classroom or in other situations
    in which remaining seated is expected
5. Does not seem to listen when spoken to directly
6. Runs about or climbs excessively in situations
    in which it is inappropriate
7. Does not follow through on instructions and fails
    to finish work
8. Has difficulty playing or engaging in leisure
    activities
9. Has difficulty organizing tasks and activities
10. Is “on the go” or acts as if “driven by a motor”
11. Avoids tasks that require sustained mental effort
12. Talks excessively
13. Loses things necessary for tasks or activities
14. Blurts out answers before questions have
      been completed
15. Is easily distracted
16. Has difficulty awaiting turn
17. Is forgetful in daily activities
18. Interrupts or intrudes on others
2. Fidgets with hands or feet or squirms in seat
4321
ADHD-RS-IV item score, mean ± SD
0−1 4321
ADHD-RS-IV item score, mean ± SD
0−1
Placebo men aged 18–39 years: (n = 20)
Placebo women aged 18–39 years: (n = 17)
LDX men aged 18–39 years: (n = 133)
LDX women aged 18–39 years: (n = 92)
A
ItemsBaseline Endpoint
1. Fails to give close attention to details or makes
    careless mistakes in schoolwork
3. Has difficulty sustaining attention in tasks or
    play activities
4. Leaves seat in classroom or in other situations
    in which remaining seated is expected
5. Does not seem to listen when spoken to directly
6. Runs about or climbs excessively in situations
    in which it is inappropriate
7. Does not follow through on instructions and fails
    to finish work
8. Has difficulty playing or engaging in leisure
    activities
9. Has difficulty organizing tasks and activities
10. Is “on the go” or acts as if “driven by a motor”
11. Avoids tasks that require sustained mental effort
12. Talks excessively
13. Loses things necessary for tasks or activities
14. Blurts out answers before questions have
      been completed
15. Is easily distracted
16. Has difficulty awaiting turn
17. Is forgetful in daily activities
18. Interrupts or intrudes on others
2. Fidgets with hands or feet or squirms in seat
4321
ADHD-RS-IV item score, mean ± SD
0−1 4321
ADHD-RS-IV item score, mean ± SD
0−1
Placebo men aged 40–55 years: (n = 12)
Placebo women aged 40–55 years: (n = 13)
LDX men aged 40–55 years: (n = 59)
LDX women aged 40–55 years: (n = 68)
B
Figure 3 ADHD-RS-IV mean item scores by adult age and sex subgroups at baseline and endpoint. (A) Shows men and women aged 18 to 39 years; (B) shows men and 
women aged 40 to 55 years.
Notes: © 1998 Guildford Press. Adapted with permission from DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, Norms, and Clinical 
Interpretation. New York, NY: Guilford Press; 1998.38 Odd numbers = inattention items; even numbers = hyperactivity/impulsivity items. Adult prompts were used in the adult 
study. Bold text represents a hyperactivity/impulsivity item.
Abbreviations: ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale IV; LDX, lisdexamfetamine dimesylate; SD, standard deviation.
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Table 1 Participant disposition and baseline demographic data






Placebo, n (%) 72 (25.3) 62 (15.0)
active, n (%) 213 (74.7) 352 (85.0)
Disposition, n (%)
completed 230 (80.7) 349 (84.3)
Discontinued 55 (19.3) 65 (15.7)
 Treatment-emergent  
adverse events
21 (7.4) 21 (5.1)
Lack of efficacy 14 (4.9) 8 (1.9)
Protocol violation 3 (1.1) 16 (3.9)
lost to follow-up 9 (3.2) 5 (1.2)
Withdrew consent 3 (1.1) 9 (2.2)
Physician decision 1 (0.4) 2 (0.5)
Other 4 (1.4) 4 (1.0)
Baseline demographic data
Age, mean (SD), y 9.0 (1.8) 35.2 (10.3)
sex, n (%)
 Female 88 (30.9) 190 (45.9)
 Male 197 (69.1) 224 (54.1)
Age groups by sex, n (%)
 Female aged 6−9 years 53 (18.6)
 Female aged 10−12 years 35 (12.3)
 Male aged 6−9 years 119 (41.8)
 Male aged 10−12 years 78 (27.4)
 Female aged 18−39 years 109 (26.3)
 Female aged 40−55 years 81 (19.6)
 Male aged 18−39 years 153 (37.0)
 Male 40−55 aged years 71 (17.1)
Race/ethnicity, n (%)
 african american 69 (24.2) 14 (3.4)
 asian 3 (1.1) 4 (1.0)
 caucasian 152 (53.3) 344 (83.1)
 hispanic 48 (16.8) 39 (9.4)
 Native american 2 (0.7) 3 (0.7)
 Other 11 (3.9) 10 (2.4)
global severity (cgi-s), n (%)
 Mildly ill 1 (0.4) 0
 Moderately ill 101 (35.4) 139 (33.6)
 Markedly ill 134 (47.0) 218 (52.7)
 severely ill 45 (15.8) 56 (13.5)
 extremely ill 4 (1.4) 1 (0.2)
Abbreviations: cgi-s, clinical global impressions-severity scale; n, number; sD, 
standard deviation; y, year.
all items (Figure 2A, left panel). At baseline, for boys and 
girls aged 10 to 12 years, there were somewhat numerically 
higher IA (odd-numbered items) scores than H/I scores 
(even-numbered items) (Figure 2B, left panel). At endpoint, 
the mean item scores for all 18 items were numerically 
decreased in the active treatment groups among the boys 
and girls aged 6 to 9 years and 10 to 12 years (Figure 2A 
and B, right panels). Likely due to the small subgroup size, 
the mean item scores for the placebo group of girls aged 6 
to 9 years were  numerically variable, with greater breadth 
of SDs at both baseline and endpoint (Figure 2A, left and 
right panels).
For adults, as in the children aged 10 to 12 years, the 
IA mean item scores tended to be numerically higher 
than the H/I mean item scores; this was especially appar-
ent among older (aged 40 to 55 years) men and women 
 (Figure 3A and B, left panels). For the subgroup of men 
aged 40 to 55 years receiving placebo, the mean baseline 
item scores were somewhat more numerically variable, 
with a broader range of SDs, likely due to the relatively 
small subgroup size. At the endpoint, the mean item scores 
for all 18 items were numerically decreased in the active 
treatment groups among the men and women aged 18 to 39 
years (Figure 3A, right panel). For the subgroups of men and 
women aged 40 to 55 years, the endpoint mean item scores 
were numerically decreased for participants in the active 
treatment groups and to some extent, for participants in the 
placebo groups (Figure 3B, right panel). In this older adult age 
group, there did not seem to be as much numerical variability 
in mean item scores at the endpoint for participants in the 
active treatment group vs the placebo group. Younger adults 
in the active treatment group had numerically decreased mean 
item scores compared with the placebo group; however, this 
group’s overall population size was about two times larger 
than that of the older adult age group.
safety
The details of the safety findings assessed in these trials 
have been previously described.30,31 In these two random-
ized, controlled trials, TEAEs were reported by 162 of 
218 (74.3%) participants in all the LDX dose groups and 
34 of 72 (47.2%) participants in the placebo group in the 
child study, and by 282 of 358 (78.8%) participants taking 
LDX (at all doses) and 36 of the 62 (58.1%) participants 
on placebo in the adult study. In the child study, the TEAEs 
with an incidence $5% in the combined LDX group were 
decreased appetite, insomnia, headache, upper abdominal 
pain, irritability, weight loss, vomiting, nausea, dizzi-
ness, and nasopharyngitis, and in the placebo group were 
 headache, cough, nasal congestion, nasopharyngitis, and 
upper abdominal pain.30 In the randomized controlled trial in 
adults, the TEAEs with an incidence $5% in the combined 
LDX group were decreased appetite, dry mouth, headache, 
insomnia, nausea, diarrhea, irritability, anxiety, upper respi-
ratory tract infection, anorexia, and initial insomnia.31 In 
both studies, LDX demonstrated a safety profile consistent 
with long-acting stimulant use.






In this set of post hoc analyses, we investigated the nature 
and severity of individual DSM-IV-TR ADHD symptoms in 
subgroups of children and adults, defined based on age and 
sex. In a previous post hoc analysis of data from a random-
ized, placebo-controlled, crossover study of LDX in children 
with ADHD, assessing behavior and performance using an 
analog classroom setting, minimal interaction effects were 
found for sex and age.39 Rather than analyze these data sets 
with a comparative statistical approach, a descriptive presen-
tation of the pattern of symptom involvement and change 
in these subgroups was chosen. In addition to the previous 
findings above, the rationale for not pursuing comparative 
statistical analysis involved a consideration of several factors, 
 including: prior commentary40,41 recommending against com-
parative statistical analysis of post hoc subgroup data sets; 
the small number of participants in many of the subgroups 
in the current study; the large number of analyses that would 
be required; and the lack of statistical power in the current 
analyses. The value of the current analysis was judged to 
be derived from examining the sex and age patterns for 
the ADHD symptom item analysis; to illustrate IA and H/I 
symptoms, showing the “pattern” of symptom involvement; 
and the relative improvement across the items.
The symptom item profiles were assessed before and after 
treatment with the long-acting stimulant LDX, to assess the 
similarities and differences in the profile of treatment-related 
changes in symptom severity. The baseline pretreatment 
ADHD-RS-IV mean item scores were numerically similar, 
regardless of age-by-sex subgroup, with the IA mean item 
scores tending to be numerically higher (more severe) than 
the H/I mean item scores, particularly among older adult 
participants. Overall, the endpoint ADHD-RS-IV mean item 
scores were numerically decreased with active treatment in 
both children and adults. The age-by-sex subgroup analysis 
showed that both IA and H/I symptoms decreased with 
active treatment among all subgroups examined, albeit with 
considerable variability. The greater variability, as shown by 
wider SDs, for some age-by-sex subgroups at either baseline 
or endpoint, especially for some subgroups receiving placebo, 
is likely to have been related to the smaller subgroup sizes 
since all the placebo groups had smaller sample sizes than 
the active treatment groups; smaller sample sizes decrease 
the precision of data and the ability to determine statistical 
relevance. With regard to baseline pretreatment symptom 
presentation, all age-by-sex subgroups generally exhibited 
broadly similar patterns and levels of symptom severity: 
for most age-by-sex subgroups, at baseline, IA mean item 
scores tended to be slightly numerically higher (ie, more 
severe) than were the H/I mean item scores, and this was 
more pronounced among older participants. It is unclear 
whether in the current post hoc analysis, the lack of definitive 
sex-related differences in symptom presentation in children 
was due to the exclusion from the present trial of individuals 
with the predominantly IA subtype, as this may be seen more 
often in females.  Consequently, these findings may differ 
from previous research because those earlier efforts reflect 
a more symptomatically homogeneous sample that includes 
the predominantly IA subtype. Nevertheless, the current 
findings are in agreement with those of Sobanski et al,23 who 
found the IA and H/I subtypes in roughly equal proportions 
of clinic-referred adult men and women with ADHD, which 
suggests that the present analysis may accurately reflect 
symptom presentation in men and women.
However, the current findings support prior research 
indicating age-related differences in symptom presenta-
tion at baseline, with older participants showing more 
pronounced IA symptoms relative to H/I symptoms. Our 
findings are in line with previous findings suggesting that 
H/I symptoms tend to decrease with increasing age while 
IA symptoms are more constant with increasing age.6−8,38 
However, it is worth noting that while this and previous stud-
ies suggest differences in symptom presentation according 
to patient age, it is not clear whether these are related to 
real differences in the presence and severity of symptoms 
or are related to different forms of symptom expression 
between younger and older individuals.9,14 Some research-
ers have argued that reported decreases in H/I may reflect 
changing manifestations not captured by the DSM-IV-TR 
criteria, rather than the true resolution of H/I symptoms.9,13 
With maturation, hyperactivity may begin to manifest as 
inner restlessness, feeling uncomfortable sitting for lengthy 
periods, or being unwilling to wait in line.13 Impulsivity 
may manifest as increased frustration or explosive emo-
tional episodes.14 In line with these arguments, in a 5-year 
longitudinal study (mean baseline age of ∼13 years), there 
was poor diagnostic stability for the major DSM-IV ADHD 
subtypes.8 The highest rates of stability were observed for 
the combined subtype (24%), while the lowest rate (11%) 
was observed for the predominantly H/I subtype. It seems 
possible that such instability may, at least in part, reflect 
an issue with the diagnostic criteria, rather than an actual 
change in ADHD subtype. Questions surrounding the 
changing profile of symptom manifestation during devel-
opment are apparent from the lack of developmentally 
appropriate descriptions of the defining symptoms for 
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individuals who are in transition from early childhood to 
middle childhood, adolescence, and adulthood,9 in the DSM-
IV-TR. The revised criteria for the DSM-5 (completed in 
2013) may help to resolve these challenges in the diagnosis 
of ADHD in older patients. A recently published study12 
of large community-based (National Comorbidity Survey 
Replication) and managed health care populations has cor-
roborated the previously mentioned finding of Millstein 
et al10 and also documented increased IA vs H/I symptom 
loading in adults with ADHD.
limitations
Several important limitations of the present post hoc analyses 
warrant consideration. The studies were not prospectively 
powered to detect differences among the subgroups exam-
ined; some sample sizes, especially in the placebo subgroups, 
were small, resulting in substantial variability in some of the 
baseline ADHD-RS-IV item scores and in the difference 
scores for LDX vs placebo. This was generally manifested 
by larger SDs for item scores and may have accounted for 
some of the variability between participants in the LDX or 
placebo groups at baseline. No tests of internal consistency, 
reliability, or factor analyses were performed, as this post hoc 
analysis was not intended to validate the ADHD-RS scale. 
Caution should be considered in generalizing the results to 
the overall ADHD population in light of a potential selection 
bias due to exclusion of the IA subtype in the pediatric trial. 
As well, the baseline severity requirements of ADHD-RS-IV 
total score $28 may have masked differences that occur in 
the general population of ADHD patients; females, as well 
as older children and adults, have been noted to express 
more IA symptomatology vs that of H/I. Importantly, since 
the pediatric trials explicitly excluded participants diagnosed 
with the predominantly IA subtype, this potentially limits the 
ability to detect differential effects of participant variables 
and treatment on the IA symptom clusters. These were explor-
atory, post hoc analyses, so groups were not matched and data 
analysis was limited to descriptive statistical comparisons. 
Formal hypothesis testing was not performed. Certain aspects 
of the previous child and adult studies limit the ability to 
generalize the findings to clinical situations, including use 
of forced-dose titration designs, relatively short treatment 
duration (4 weeks), exclusion of adolescent participants (aged 
13 to 17 years), and enrollment of clinic-referred participants 
with moderate to severe ADHD symptoms.
In conclusion, these post hoc subgroup analyses sug-
gest that the presentation of individual DSM-IV-TR ADHD 
symptoms, for those with combined or H/I subtype ADHD, 
was generally similar regardless of participants’ sex, but with 
older children and adults tending to exhibit more severe IA 
than H/I symptoms. Moreover, the endpoint ADHD-RS-IV 
items mean scores were generally numerically lower after 
active treatment for most IA and H/I symptom items in 
most of the age-by-sex subgroups, suggesting that ADHD 
symptoms are broadly responsive to effective treatment. The 
current findings add to the growing literature surrounding 
age- and sex-related differences in ADHD symptom pre-
sentation and treatment response, and this continues to be 
an important area in need of further research.
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